Home
About US
About GenSci
Our Values
Production Sites
Counterfeiting
Contact Us
Science
R&D
R&D Centers
Technology
Driven by state-of-the-art Technology Platforms
Collaborations & Partnerships
News
Press Releases
GenSci Invites You to Meet Us at Arab Health 2025
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024
World ADC San Diego 2024: GenSci showcases two innovative pipeline programs
Welcome to Visit Us at MEDICA 2024
GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Action
Meet GenSci at CPhI Milan 2024
GenSci showcases the innovative pipelines at ChinaBio®
GenSci Invites You to Meet Us at Pharmedi Vietnam 2024
GenSci098 Injection Obtains Implied License For Clinical Trials of FDA
Jintrolong® New Dosage Form of Long-acting Somatropin Injection Approved
Clinical Trial Commencement of GenSci098 Injection Approved
Zhejiang University – GenSci Joint Research Center of Children’s Health established
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection Accepted
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation Agreement
GenSci Invites you to join us in CPHI South East Asia 2024
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® Approved
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®
Visit GenSci at CPhI China 2024
NMPA Approves Genakumab Injection for Clinical Trial Commencement
Jintrolong® PEG-SOMATROPIN from GenSci highlighted at ECE 2024
R&D Progress: NMPA Approves Genakumab to the Market
GenSci Launches Global Innovation Hub in Shanghai
Sustainability